Trusted by 100,000+ International Patients
CAR-T: India vs Malaysia
Cost, Quality & Recovery Compared
$80000
India Starting Cost
$75000
Malaysia Starting Cost
See how these top medical tourism destinations compare for CAR-T.
| Comparison Factor | India | Malaysia | Winner |
|---|---|---|---|
| Average Cost (in USD) | 80000 - 120000 | 75000 - 125000 | Both Equal |
| Success Rate (Min and Max) | 60%–85% response | 60% – 85% response (indication dependent) | Both Equal |
| Advanced Technology | Cell therapy + ICU CRS/ICANS | Emerging CAR-T therapy programmes in select leading oncology centres, supported by GMP-compliant cell processing collaborations, apheresis units, advanced molecular diagnostics, next-generation sequencing, and specialised haematology-oncology ICUs equipped to manage CRS and ICANS complications. | Both Equal |
| JCI Accredited Hospitals | 40+ | 25+ | India |
| Visa Process | Medical Visa (3–7 days) | Medical Visa / eVisa / Social Visit Pass (2–5 working days; nationality dependent) | Both Equal |
| Hospital Stay (typical) | 14–28 days | 14–28 days | Both Equal |
| Patient Journey Complexity | High (cell therapy pathway) | Very High (complex personalised immunotherapy involving cell harvesting, genetic modification, conditioning chemotherapy, and intensive monitoring) | Both Equal |
*Costs are estimates and may vary based on hospital, complexity, and package inclusions. See detailed cost breakdown below
Understand exactly where your money goes. Both countries offer all-inclusive packages, but here's how the costs typically break down.
Best for Budget-Conscious Patients
Offered Package Price (Additional Cost Excluded)
Best for Flexible Donor Requirements
Offered Package Price (Additional Cost Excluded)
Want a personalized cost estimate based on your specific condition?
Get Your Free QuoteBoth India and Malaysia maintain world-class healthcare standards with internationally accredited hospitals and highly trained medical professionals.
40+ JCI hospitals; major oncology centres follow standardised infection control and ICU pathways for CRS/ICANS.
Response benchmarks depend on indication and baseline disease; best outcomes in ICU‑ready tertiary centres.
Governed under national medical governance and institutional protocols for advanced therapies.
Malaysia hosts internationally accredited hospitals, including JCI-certified oncology centres, ensuring adherence to global standards in cancer care and emerging cellular therapies.
CAR-T therapy outcomes are evolving, with selected centres demonstrating encouraging response rates supported by advanced diagnostics and experienced haematology-oncology teams.
Healthcare is regulated by the Ministry of Health Malaysia (MOH), ensuring compliance with international safety, ethical, and clinical governance standards for advanced therapies.
| Quality Metric | India | Malaysia |
|---|---|---|
Accredited Hospitals | 40+ | 25+ |
Average Success Rate | 60%–85% response | 60% – 80% response |
Post‑op / 1‑year outcome signal | Indication‑dependent | Indication-dependent |
Top Speciality Hubs | Delhi, Mumbai, Chennai | Kuala Lumpur |
Both countries have highly qualified and experienced medical specialists trained at premier institutions worldwide. Here's what sets them apart.
India has specialised cancer centres with experienced haematologists and cellular therapy experts offering advanced CAR-T treatment.
Leading Indian hospitals manage a high volume of complex cancer cases, contributing to strong clinical expertise in advanced therapies.
Haematologists and oncology specialists trained in immunotherapy, stem cell transplantation, and advanced cancer treatments with growing expertise in CAR-T and cellular therapies.
Selected tertiary cancer centres manage complex haematological malignancies with multidisciplinary teams; CAR-T experience is developing compared to global leaders.
All surgeons listed on Medigence are verified for their medical license, board certifications, hospital affiliations, and patient outcomes. We conduct background checks and regularly update our database to ensure you're connected with the best medical professionals.
Beyond medical excellence, your comfort during treatment matters. Compare the patient experience at top hospitals in both destinations.
World-class hospitals, exceptional value
Many hospitals in India are equipped with advanced oncology units, modern laboratories, and intensive care facilities to support CAR-T therapy.
Luxury healthcare experience
Advanced oncology centres equipped with apheresis units, specialised haematology wards, transplant units, ICU facilities, and access to GMP-compliant labs through regional or international collaborations.
Plan your medical journey with confidence. Here's everything you need to know about travel, visas, and accommodation in both countries.
We provide end-to-end travel assistance including visa facilitation, airport pickups, hotel bookings near your hospital, and local support throughout your stay. Our patient coordinators handle all logistics so you can focus on recovery.
Understanding the recovery process helps you plan better. Here's what to expect after CAR-T in both countries.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to stay near the treatment centre for regular monitoring, blood tests, and immediate management of any delayed complications.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
In-person follow-ups recommended at 3, 6, 12 months. Telemedicine available.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to remain near the treatment centre for regular monitoring, blood tests, and immediate management of any complications that arise.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
Comprehensive telemedicine follow-up program. Return visits at 6, 12 months if possible.
CAR-T recipients require lifelong immunosuppressant medications. Ensure you have a plan for obtaining these medications and regular blood monitoring in your home country before traveling abroad for surgery.
Every medical procedure carries risks. We believe in complete transparency so you can make a fully informed decision about your CAR-T journey.
An immune reaction after CAR-T infusion causes fever, low blood pressure, and flu-like symptoms.
Temporary neurological symptoms such as confusion, headache, or speech difficulty may occur.
The weakened immune system after therapy increases the risk of bacterial or viral infections.
Reduced levels of red cells, white cells, or platelets may increase the risk of infection or bleeding.
Side effects may occur due to supportive medications, such as chemotherapy or immune-related treatments, used during CAR-T therapy.
The right choice depends on your specific situation. Here's a clear guide to help you decide which destination aligns with your needs.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Our medical tourism experts can analyze your case and recommend the best destination based on your medical history and budget.
Follow this step-by-step framework to make the right choice for your CAR-T journey.
Assess the type and stage of cancer to determine eligibility and urgency for CAR-T therapy.
Plan the overall cost, including treatment, travel, accommodation, and unexpected medical expenses.
Ensure you can stay near the treatment centre for monitoring during the early recovery period.
Provide detailed reports in advance so specialists can evaluate eligibility and create a treatment plan.
Arrange continued monitoring and coordination with local doctors for recovery and long-term outcomes.
Let our medical tourism experts guide you through the process. We'll help you:
No obligation • Free consultation • Response within 24 hours
Surgical Oncologist
15 Years of Experience
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More
